Loading patent…
AssigneesInstitut National de la Sante et de la Recherche Medicale, Sorbonne Universite, Université Paris Cité, Assistance Publique-HôPitaux De Paris (Aphp)
InventorsSandra REBOUISSOU, Pierre MOREL-RIBEIRO, Jean-Charles NAULT, Théo HIRSCH, Jessica ZUCMAN-ROSSI, Jill PILET
Estimating the term…
Pediatric liver cancers (PLC) are rare tumors. In particular, hepatoblastomas are usually treated with cisplatin-based neoadjuvant chemotherapy followed by surgical removal of the tumor and adjuvant chemotherapy. However, some hepatoblastomas develop resistance to chemotherapy during the initial neoadjuvant chemotherapy or after tumor recurrence, and the molecular determinants of cisplatin resistance are yet to be discovered. In contrast to hepatoblastomas, pediatric HCCs respond poorly to chemotherapy, and as in adults, they have a poor prognosis if not completely removed by surgery. There is thus an urgent need for new therapeutic strategies to overcome this resistance. Now the inventors demonstrate that Elimusertib and Cisplatin combination shows synergistic efficacy on tumor cell viability inhibition in pediatric liver cancer cell lines. The present invention thus relates to the combination of cisplatin and Elimusertib for the treatment of pediatric liver cancers.
A method of treating a pediatric liver cancer (PLC) in a patient in need thereof and/or for enhancing the therapeutic efficacy of cisplatin administered to the patient as part of a treatment regimen for the PLC comprising administering to the patient a therapeutically effective combination of cisplatin with elimusertib, wherein administration of the combination results in enhanced therapeutic efficacy relative to the administration of cisplatin alone.
(canceled)
A method of preventing relapse in patient suffering from a pediatric liver cancer (PLC) after a treatment with cisplatin comprising administering to the patient a therapeutically effective amount of cisplatin in combination with elimusertib.
A method of preventing resistance to cisplatin therapy in a patient suffering from a pediatric liver cancer (PLC) comprising administering to the patient a therapeutically effective amount of cisplatin in combination with elimusertib.
Dependencies are inferred from the claim text.